Peptide Handling
Cloudy Peptide After Reconstitution: What the Labels Say It Means
A reconstituted peptide should normally be clear. Foam settles and a chill can pass; cloudiness or particles that stay are the point at which every approved label says stop. This page sets out what U.S. labels for seven reconstituted and suspension products say a correct solution looks like, the two temporary causes they recognise, and how that reading carries over to research material that has no label. Research-material handling education only.
The short answer
- Clear is the expected result. Every reconstituted peptide or protein label read for this page describes the finished solution as clear, and several as colorless.
- Two causes are temporary. Foam from mixing settles, and one label notes that some cloudiness may occur after refrigeration. Both are judged by whether they pass.
- Persistent cloudiness or particles mean stop. The labels agree: a solution that stays cloudy, or shows particles, is not used.
- Shaking is the avoidable cause. One label says vigorous mixing will make the solution cloudy; another says shaking may denature the active ingredient.
- Research material has no label to compare against. The defensible reading is the same: if it does not become clear, treat it as failed.
What a correct solution looks like, label by label
Approved injectable products describe their own appearance, and the descriptions for reconstituted peptide and protein products are strikingly uniform. The last row is there on purpose: it shows that the reference is the product’s own description, not a general rule that cloudy is bad.
| Product | Expected appearance | What the label says about cloudiness |
|---|---|---|
| Somatropin (GENOTROPIN), powder + diluent | Clear and colorless | Not to be used if the solution is cloudy or contains particulate matter. “Do not shake; shaking may cause denaturation of the active ingredient.” |
| Somatropin (HUMATROPE), powder + diluent | Clear, without particles | Do not shake. If cloudy or particulate, do not use. For the cartridge: if the liquid is cloudy, gently mix 10 more times; if it is still cloudy, do not use it. |
| Somatropin (ZOMACTON), powder + diluent | Clear once completely dissolved | “Shaking or vigorous mixing will cause the solution to be cloudy.” Some cloudiness may occur after refrigeration; if it persists, or particles are seen, do not use. |
| Somatropin (OMNITROPE), powder + diluent | Clear and colorless after mixing | Aim the diluent against the glass wall to avoid foam; swirl gently, do not shake. Cloudy or particulate: do not use. |
| Tesamorelin (EGRIFTA SV), powder + sterile water | Clear, colorless, no particles | Diluent down the inside wall “to avoid foaming”; do not shake. Cloudy, discolored or particulate: do not use. |
| Cetrorelix (CETROTIDE), powder + diluent | Clear and without residues | Swirl gently until clear; do not shake, which creates bubbles. |
| Insulin isophane (HUMULIN N), suspension | White and uniformly cloudy | The reverse case: do not use it if it looks clear, or has lumps or particles. |
Sources: U.S. prescribing information and instructions for use for GENOTROPIN, HUMATROPE, ZOMACTON, OMNITROPE, EGRIFTA SV, CETROTIDE and HUMULIN N, read through openFDA on 15 October 2026 (label versions effective July 2025 to August 2026).
The two kinds of cloudiness that can pass
Foam and fine bubbles from mixing. The labels treat foam as something to prevent rather than a defect in the product: the EGRIFTA SV and OMNITROPE instructions direct the diluent down the inside wall of the vial so it does not hit the powder and foam, and the CETROTIDE instructions warn that shaking creates bubbles. Bubbles rise and the haze they cause clears; a solution that is still hazy once they have gone is a different problem.
Cloudiness after refrigeration. The ZOMACTON label states that some cloudiness may occur after refrigeration, and rules the solution out only if the cloudiness persists or particles are seen. The HUMATROPE cartridge instructions set a similar limit in practice: if the liquid looks cloudy, mix gently ten more times, and if it is still cloudy, do not use it. Both labels allow a second look. Neither allows a third explanation.
Why shaking is the cause you control
The labels say this in plain words. ZOMACTON: “shaking or vigorous mixing will cause the solution to be cloudy.” GENOTROPIN: “shaking may cause denaturation of the active ingredient.” Six of the seven labels in the table tell the user not to shake; the alternative they give is to swirl gently until the powder has dissolved. The general reconstitution procedure, without any dose arithmetic, is on our how to reconstitute peptides page.
When it does not clear: what the eye cannot tell you
Persistent haze means something in the vial is not in solution. It may be powder that never dissolved, protein that has clumped, or contamination; a visual check cannot separate those, and none of them is made safe by waiting longer. That is why the labels do not ask the user to diagnose the cause — they simply say not to use the product.
For research material there is a second gap. A certificate of analysis reports the purity of the powder as tested at the lab; it says nothing about the solution in front of you after mixing, storage and handling. Our certificate of analysis guide explains what each result does and does not establish. With no label describing the expected appearance, the only defensible reading is the one every label shares: a solution that does not become clear is treated as failed.
Particles are a separate signal
Labels list particles alongside cloudiness, and both GENOTROPIN and EGRIFTA SV also name discoloration. The standard wording is to inspect the solution visually for particulate matter and discoloration “whenever solution and container permit.” Not every particle comes from the peptide: a needle passing through a rubber stopper can cut fragments from it, many of them hard to see with the naked eye. The rates and what they mean are on our vial coring page.
Check the diluent first
The Bacteriostatic Water for Injection label sets the same standard for the water itself: “Do not use unless the solution is clear and seal intact.” It also asks for reconstituted drugs to be inspected “for clarity (if soluble) and freedom from unexpected precipitation or discoloration.” Checking the diluent before it goes into the vial removes one possible source of haze before any peptide is involved. Which diluent approved peptide products are actually packed with is covered on best reconstitution solution for peptides. Medibact supplies USP-grade bacteriostatic water produced in an FDA-registered U.S. facility, in the 30 mL multiple-dose format, for research use only.
Where this sits in the rest of the reference
FAQ
Why is my peptide cloudy after reconstitution?
A solution looks cloudy when something in it is not dissolved: powder that has not gone into solution yet, fine bubbles from vigorous mixing, protein that has clumped together, or contamination. The approved labels for peptide and protein products name two harmless, temporary causes — foam from shaking and some cloudiness after refrigeration — and treat everything that does not clear as a reason not to use the product. Looking at the vial cannot tell you which cause you have.
Is a cloudy peptide bad?
Every label for a reconstituted peptide or protein product read for this page says the same thing: if the solution stays cloudy or contains particles, do not use it. GENOTROPIN, HUMATROPE, OMNITROPE and EGRIFTA SV all say so in nearly the same words. Unlabeled research material has no label stating what it should look like, so the only defensible reading is the same one: a solution that does not become clear is treated as failed.
Can a cloudy peptide solution clear up?
Sometimes, and the labels say exactly when. Foam from mixing settles. The ZOMACTON label says some cloudiness may occur after refrigeration and only rules the solution out if the cloudiness persists. The HUMATROPE cartridge instructions allow gently mixing ten more times before deciding. What no label allows is using a solution that is still cloudy after that.
Does shaking a peptide vial make it cloudy?
It can. The ZOMACTON label states that shaking or vigorous mixing will cause the solution to be cloudy, and the GENOTROPIN label says shaking may cause denaturation of the active ingredient. That is why the labels for GENOTROPIN, HUMATROPE, OMNITROPE, EGRIFTA SV, CETROTIDE and ZOMACTON all say not to shake, and several tell you to run the diluent down the inside wall of the vial to avoid foam.
Is a cloudy solution ever normal?
Yes, when the product is a suspension. HUMULIN N is labeled as a white, cloudy suspension that should look uniformly cloudy after mixing, and its label says not to use it if it looks clear. The reference is always the product’s own description: what is a defect in one formulation is the expected appearance of another.
Should bacteriostatic water be cloudy?
No. The Bacteriostatic Water for Injection label says not to use it unless the solution is clear and the seal is intact. Check the diluent before it goes into the vial; a cloudy or particle-bearing diluent is excluded before any peptide is involved.
What if I see particles or flakes rather than haze?
Labels treat visible particles exactly like persistent cloudiness: do not use. Particles can also come from the vial itself — a needle can cut fragments from the rubber stopper, which our vial coring page covers — so particles are a reason to stop, not something to wait out.
Is this medical advice?
No. This page is research-material handling education drawn from published U.S. labeling. It contains no dosing, route or timing instruction, and the label instructions it quotes describe those specific approved products. Medibact is not affiliated with Eli Lilly, Pfizer, Sandoz, Ferring, Novo Nordisk, Theratechnologies, EMD Serono or any manufacturer named here.
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.